PCVX
Income statement / Annual
Last year (2023), Vaxcyte, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Vaxcyte, Inc.'s net income was -$402.27 M.
See Vaxcyte, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$75.00 M |
$9.20 M |
$1.80 M |
$1.41 M |
$1.23 M |
$1.04 M |
$0.00 |
| Gross Profit |
-$75.00 M |
-$9.20 M |
-$1.80 M |
-$1.41 M |
-$1.23 M |
-$1.04 M |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$332.34 M
|
$169.45 M
|
$78.41 M
|
$73.56 M
|
$45.61 M
|
$30.15 M
|
$12.79 M
|
| General & Administrative
Expenses |
$60.70 M
|
$39.81 M
|
$25.26 M
|
$16.02 M
|
$8.55 M
|
$5.39 M
|
$5.05 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$60.70 M
|
$39.81 M
|
$25.26 M
|
$16.02 M
|
$8.55 M
|
$5.39 M
|
$5.05 M
|
| Other Expenses |
$0.00 |
-$1.93 M |
-$1.59 M |
-$2.48 M |
-$237,000.00 |
$5.18 M |
$0.00 |
| Operating Expenses |
$468.04 M |
$207.33 M |
$102.09 M |
$87.10 M |
$53.92 M |
$35.53 M |
$17.40 M |
| Cost And Expenses |
$468.04 M |
$207.33 M |
$102.09 M |
$87.10 M |
$53.92 M |
$35.53 M |
$17.40 M |
| Interest Income |
$62.91 M |
$8.36 M |
$344,000.00 |
$244,000.00 |
$632,000.00 |
$903,000.00 |
$164,000.00 |
| Interest Expense |
$0.00 |
$2,000.00 |
$7,000.00 |
$7,000.00 |
$40,000.00 |
$75,000.00 |
$0.00 |
| Depreciation &
Amortization |
$3.16 M
|
$9.20 M
|
$1.80 M
|
$1.41 M
|
$1.23 M
|
$1.04 M
|
$625,000.00
|
| EBITDA |
-$464.89 M
|
-$214.29 M
|
-$98.28 M
|
-$87.81 M
|
-$49.00 M
|
-$28.37 M
|
-$17.21 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$65.78 M
|
$8.77 M
|
$3.59 M
|
$364,000.00
|
$3.88 M
|
$6.05 M
|
$595,000.00
|
| Income Before Tax |
-$402.27 M |
-$223.49 M |
-$100.08 M |
-$89.22 M |
-$50.27 M |
-$29.49 M |
-$17.24 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$16.16 M |
$7,000.00 |
-$1.40 M |
$3.23 M |
$6.12 M |
$0.00 |
| Net Income |
-$402.27 M |
-$239.64 M |
-$100.08 M |
-$87.82 M |
-$53.50 M |
-$29.49 M |
-$17.24 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-4.14 |
-3.69 |
-1.93 |
-1.72 |
-1.09 |
-1.15 |
-4.84 |
| EPS Diluted |
-4.14 |
-3.69 |
-1.93 |
-1.72 |
-1.09 |
-1.15 |
-4.83 |
| Weighted Average Shares
Out |
$97.16 M
|
$64.88 M
|
$51.92 M
|
$51.07 M
|
$48.86 M
|
$25.60 M
|
$3.57 M
|
| Weighted Average Shares
Out Diluted |
$97.16 M
|
$64.88 M
|
$51.92 M
|
$51.07 M
|
$48.86 M
|
$25.60 M
|
$3.57 M
|
| Link |
|
|
|
|
|
|
|
